• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Immuno-Oncology 360°

March 16, 2022
March 18, 2022
New York Marriott Brooklyn Bridge, New York City

IO360° convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. The 8th Annual Immuno-Oncology 360° delivers three key benefits:

  1. Access to KOLs driving the science
  2. Partnership opportunities with all stakeholders in Immuno-Oncology
  3. Presentations on the latest data impacting the science, clinical and business advancements in Immuno-Oncology

Come visit us at booth #26.

Session Information

Title: Imaging Response After Unconfirmed Progression: Data Trends from Clinical Trials Utilizing iRECIST

Date: Wednesday, March 16th, 2022

Time: 1:20 p.m. – 1:35 p.m. EST

Location: Track A

The iRECIST approach is primarily focused on confirmation of radiographic disease progression in the setting of immunotherapy. With the unique ability to look across multiple studies and indications, this discussion shares data trends from iRECIST trials in the context of confirmed and unconfirmed progressive disease.


Jack Skinner, PhD

Advisor of Medical and Scientific Affairs at Clario

Jack’s focus is in support of the oncology therapeutic area where he provides input on trial design, review methodology and development of operational strategies for new imaging criteria. His expertise extends to optimization of imaging documentation and creation of workflows for novel image analysis approaches. Prior to positions with various CROs, Dr. Skinner worked at the National Comprehensive Cancer Network where he developed the NCCN Imaging Appropriate Use Criteria. Dr. Skinner earned his PhD in Biomedical Engineering from Vanderbilt University. His post-doctoral research focused on the development of advanced MRI techniques for evaluating late stage brain cancer.